Rho kinase activation mediates adrenergic and cholinergic smooth muscle contractile responses in the mouse prostate gland

2013 ◽  
Vol 721 (1-3) ◽  
pp. 313-321 ◽  
Author(s):  
Carl W. White ◽  
Jennifer L. Short ◽  
Sabatino Ventura
1995 ◽  
Vol 29 (1) ◽  
pp. 15-21 ◽  
Author(s):  
Kelvin G. M. Brockbank ◽  
Mark G. Davies ◽  
Shirley M. Fields ◽  
Per-Otto Hagen

2013 ◽  
Vol 708 (1-3) ◽  
pp. 14-20 ◽  
Author(s):  
Nouval Shahab ◽  
Shunichi Kajioka ◽  
Ryosuke Takahashi ◽  
Maya Hayashi ◽  
Shinsuke Nakayama ◽  
...  

1985 ◽  
Vol 15 (2) ◽  
pp. 173-178 ◽  
Author(s):  
S. LOUIE ◽  
J. J. KRZANOWSKI ◽  
S. C BUKANTZ ◽  
R. F. LOCKF.Y

1977 ◽  
Vol 232 (1) ◽  
pp. H59-H66
Author(s):  
V. S. Krishnamurty ◽  
H. R. Adams ◽  
T. C. Smitherman ◽  
G. H. Templeton ◽  
J. T. Willerson

The influence of hyperosmotic mannitol on vascular smooth muscle contractile responses was examined in isolated arterial preparations. Vasoconstrictor effects of norepinephrine (NE) and potassium chloride (K+) in the perfused central artery of the rabbit's ear and in perfused mesenteric arteries of cats were significantly inhibited by infusion with Krebs bicarbonate solution made hyperosmotic with mannitol (50–200 mosM increase). Similarly, the magnitude and duration of vasoconstrictor responses to transmural stimulation of the central ear artery of the rabbit were decreased by hyperosmotic mannitol (50 mosM). Mannitol (50 mosM) produced a decrease in perfusion pressure when perfusion pressure was maintained at an increased level by K+ (60 mM). Mannitol-induced vasodilatation was not affected by ethacrynic acid (1.5 X 10(-5) M), beta adrenergic blockade or by the development of tachyphylaxis to the vasodilator effects of nitroglycerin. The concentration of cyclic adenosine-monophosphate was not changed by mannitol. Isotonic mannitol also inhibited NE-induced contractile responses. These data indicate that hyperosmotic mannitol produces vasodilatation in isolated arterial smooth muscle by a mechanism(s) that appears dissimilar from that of several other vasodilator substances and suggest that hypertonicity may not be the only factor involved in the vasodilator effect of mannitol.


2008 ◽  
Vol 295 (2) ◽  
pp. C358-C364 ◽  
Author(s):  
Yusuke Mizuno ◽  
Eiji Isotani ◽  
Jian Huang ◽  
Hailei Ding ◽  
James T. Stull ◽  
...  

Ca2+/calmodulin (CaM)-dependent phosphorylation of myosin regulatory light chain (RLC) in smooth muscle by myosin light chain kinase (MLCK) and dephosphorylation by myosin light chain phosphatase (MLCP) are subject to modulatory cascades that influence the sensitivity of RLC phosphorylation and hence contraction to intracellular Ca2+ concentration ([Ca2+]i). We designed a CaM-sensor MLCK containing smooth muscle MLCK fused to two fluorescent proteins linked by the MLCK CaM-binding sequence to measure kinase activation in vivo and expressed it specifically in mouse smooth muscle. In phasic bladder muscle, there was greater RLC phosphorylation and force relative to MLCK activation and [Ca2+]i with carbachol (CCh) compared with KCl treatment, consistent with agonist-dependent inhibition of MLCP. The dependence of force on MLCK activity was nonlinear such that at higher concentrations of CCh, force increased with no change in the net 20% activation of MLCK. A significant but smaller amount of MLCK activation was found during the sustained contractile phase. MLCP inhibition may occur through RhoA/Rho-kinase and/or PKC with phosphorylation of myosin phosphatase targeting subunit-1 (MYPT1) and PKC-potentiated phosphatase inhibitor (CPI-17), respectively. CCh treatment, but not KCl, resulted in MYPT1 and CPI-17 phosphorylation. Both Y27632 (Rho-kinase inhibitor) and calphostin C (PKC inhibitor) reduced CCh-dependent force, RLC phosphorylation, and phosphorylation of MYPT1 (Thr694) without changing MLCK activation. Calphostin C, but not Y27632, also reduced CCh-induced phosphorylation of CPI-17. CCh concentration responses showed that phosphorylation of CPI-17 was more sensitive than MYPT1. Thus the onset of agonist-induced contraction in phasic smooth muscle results from the rapid and coordinated activation of MLCK with hierarchical inhibition of MLCP by CPI-17 and MYPT1 phosphorylation.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 2580-2580
Author(s):  
Mário Angelo Claudino ◽  
Carla Fernanda Franco-Penteado ◽  
Marcus A.F. Corat ◽  
Ana Paula Gimenes ◽  
Kleber Yotsumoto Fertrin ◽  
...  

Abstract Abstract 2580 Poster Board II-557 Genitourinary infection and urinary retention have been related to impaired urinary concentrating ability and altered urinary volume in sickle cell disease (SCD) patients. This condition may be associated with changes in the detrusor smooth muscle (DSM) reactivity. Berkeley transgenic SCD mice display several clinical manifestations similar to those seen in humans, but no studies assessing the alterations of DSM reactivity in SCD mice have been performed. DSM contractions are a consequence of the activation of muscarinic receptors that promote stimulation of phospholipase C, with increased formation of inositol trisphosphate and diacylglycerol to release calcium (Ca2+) from intracellular stores, leading to bladder emptying. The Ca2+-independent RhoA/Rho-kinase pathway is also involved in the regulation of bladder smooth muscle tone by alteration of the sensitivity of contractile proteins for Ca2+. Changes in the contraction mechanisms of DSM may contribute to bladder dysfunction. The aim of this study was to evaluate the contractile mechanisms of isolated DSM of transgenic SCD mouse. SCD (SS) and C57BL/6 (CTL) mice tissues were removed and mounted in 10ml organ baths containing Krebs solution at 37°C and continuously bubbled with a mixture of 95%O2:5%CO2 (pH 7.4). Tissues were stretched to a resting tension of 10 mN and allowed to equilibrate for 60 minutes. Changes in isometric force were recorded using a PowerLab400 Data Acquisition System. Cumulative concentration-response curves to muscarinic agonist carbachol (CCh; 0.01–100 μM) were obtained in the absence and presence of the Rho-kinase inhibitor Y-27632 (1–10 μM). Cumulative concentration-response curves were constructed to hyperpolarizing solution, potassium chloride (KCl; 1–300 mM) and calcium chloride (CaCl2; 0.01–100 mM). Frequency-response curves for electrical field stimulation (EFS; 1–32 Hz) were obtained in strips in the absence and presence of non-selective muscarinic antagonist atropine (1 μM) or purinergic receptor antagonist suramin (100 μM). Cumulative addition of the CCh produced concentration-dependent contractile responses in DSM, although the potency (pEC50) did not change in SS mice (5.80±0.02) compared with CTL mice (5.69±0.05). In contrast, the maximal response (Emax) was significantly reduced in SS mice (4.20±0.42mN) compared with CTL mice (9.96±1.77mN). In addition, the pEC50 and Emax elicited by CCh were reduced in the presence of Y-27632; however, no change was observed among all group studies. Cumulative addition of the KCl produced concentration-dependent contraction in DSM, and both pEC50 (0.98±0.08) and Emax (7.63±1.03mN) were significantly reduced in SS mice, compared with CTL mice (1.24±0.07; 11.24±0.84mN, respectively). CaCl2 produced concentration-dependent contractile responses, the pEC50 did not change in SS mice (2.00±0.06); however, the Emax was significantly reduced (10.1±0.25mN) when compared to CTL mice (1.92±0.05; 17.8±2.3mN). EFS-induced contractions in DSM of SS mice were decreased at significantly higher frequencies than compared to CTL mice. In addition, EFS-induced contractions in DSM were significantly decreased in the presence of atropine and suramin in both SS mice and CTL mice, but no change was observed among all group studies. Our study shows that SS mice exhibit impaired contractile responses to muscarinic agonist, KCl, CaCl2 and EFS, with no involvement of the Rho-kinase signaling pathway. This bladder dysfunction may contribute to the increased risk of urinary tract infections observed in SCD patients. Further studies are necessary to better understand the relationship between DSM reactivity alterations and genitourinary manifestations in SCD. Disclosures: No relevant conflicts of interest to declare.


2004 ◽  
Vol 13 (3) ◽  
pp. 84-85
Author(s):  
Zhenheng Guo ◽  
Wen Su ◽  
Shannon Allen ◽  
Huan Pang ◽  
Ming C Gong

Sign in / Sign up

Export Citation Format

Share Document